香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2675） 截至2025年12月31日止年度 全年業績公告 董事會欣然宣佈本集團截至2025年12月31日止年度之經審核綜合財務業績，連同 截至2024年12月31日止年度之比較數字，載列如下。 於本公告中，「我們」指本公司及（如文義所指）本集團。本公告所載若干金額及百 分比數字已作約整，或已約整至小數點後一位或兩位。任何表格、圖表或其他部 分總金額與所列金額總數之間如有任何差異，均因約整所致。 財務摘要 下表載列我們截至2025年12月31日止年度之主要財務數據，連同截至2024年12 月31日止年度之比較數字及變動（以百分比列示）。 | | 截至12月31日止年度 | | | | --- | --- | --- | --- | | | 2025年 | ...

深圳市精鋒醫療科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，將 於2026年3月27日（星期五）舉行董事會會議，以考慮及批准（其中包括）本公司及 其附屬公司截至2025年12月31日止年度的年度業績及其刊發，並考慮建議派發末 期股息（如有），以及處理其他事項。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2675） 董事會會議通告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 承董事會命 深圳市精鋒醫療科技股份有限公司 董事會主席兼執行董事 王建辰博士 香港, 2026年3月17日 於本公告日期，本公司董事會包括(i)執行董事王建辰博士、高元倩博士及吳夢媛 女士；(ii)非執行董事盛利先生、陳剛先生及邱翔先生；及(iii)獨立非執行董事楊 帆先生、張國光先生及劉英傑先生。 ...

Dear Non-Registered Shareholder, Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 (A joint stock company established in the People's Republic of China with limited liability) (於中華人民共和國註冊成立的股份有限公司) （Stock Code 股份代號：2675） 11 March 2026 以電子方式發布公司通訊之安排 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 2.07A 條，深圳市精鋒醫療科技股份有限公司（「本公司」）已 採納以電子方式發佈公司通訊。所有公司通訊均透過本公司網站（www.edgemed.cn）及聯交所網站（www.hkexnews.hk）（「網站版本」）以電 子方式提供並僅會於要求時才發送印刷本。 閣下可於本公司網站及聯交所網站瀏覽本公司的中、英文版本公司通訊的網站版本。 Arrangement of Electronic Dissemination of Corporate Communi ...

登記股東之名稱及地址 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2675） 2026 年 3 月 11 日 尊敬的登記股東 本公司將在本公司網站（www.edgemed.cn）及聯交所網站（www.hkexnews.hk）上發佈公司通訊。 發佈公司電子通訊之安排 簡介 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 2.07A 條 1 以及深圳市精鋒醫療 科技股份有限公司（「本公司」）的公司章程，本公司將以電子通訊方式向其股東 3 發佈本公司日後的公司通訊 （「公司通訊」2），並僅應股東要求向其寄發印刷本形式的公司通訊。 安排 1. 可供採取行動的公司通訊 4 本公司將以電子通訊方式（通過電子郵件）向股東個別地發送可供採取行動的公司通訊。如果本公司沒有獲 取股東的電子郵箱地址或其提供的電子郵箱地址無效 5，本公司將以印刷本形式向其發送可供採取行動的公 司通訊，連同一份索取股東有效電子郵箱地址的表格，以便將來以電子通訊方式發送可供採取行動的公司通 訊。 2. 公司通訊 本公司不會 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02675 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 323,602,948 | RMB | | 1 RMB | | 323,602,948 | | 增加 / 減少 (-) | | | 4,158,300 | | | RMB | | 4,158,300 | | 本月底結存 | | | 327,761,248 | RMB | | 1 RMB | | 327,761,248 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | ...

Group 1 - The overall market size of surgical robots in China is expected to grow from 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, with a CAGR of approximately 34% [1] - The market for laparoscopic surgical robots is projected to have a CAGR of about 29% from 2024 to 2032, driven by the release of pricing directories and increased penetration rates [1] - The orthopedic surgical robot market is anticipated to grow at a CAGR of around 41% during the same period, benefiting from the implementation of pricing directories and accelerated hospital admissions [1] Group 2 - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will lead to a continuous increase in consumables, generating stable revenue and cash flow [2] - The global market for leading surgical robot companies has surpassed 1 trillion RMB, with significant growth potential in penetration rates and market size [2] - AI is expected to empower surgical robots to achieve autonomous operations, further enhancing industry penetration rates and improving valuations of related companies [2] Group 3 - Related Hong Kong stocks in the surgical robot sector include Precision Medicine-B (02675), MicroPort Scientific Corporation-B (02252), and Kangji Medical (09997) [3]

Group 1 - The overall market size of surgical robots in China is expected to grow from 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, with a CAGR of approximately 34% [1] - The market for laparoscopic surgical robots is projected to have a CAGR of about 29% from 2024 to 2032, driven by the release of pricing directories and increased penetration rates [1] - The orthopedic surgical robot market is anticipated to grow at a CAGR of around 41% during the same period, supported by the implementation of pricing directories and increasing hospital admissions [1] Group 2 - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will drive continuous consumption of consumables, leading to stable revenue and cash flow [2] - The global market for leading surgical robot companies has surpassed 1 trillion RMB in market value, with significant growth potential in penetration rates and market size [2] - AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing some surgical procedures performed by doctors, which will benefit industry penetration rates and enhance company valuations [2] Group 3 - Related Hong Kong stocks in the surgical robot sector include Precision Surgery-B (02675), MicroPort Scientific-B (02252), and Kangji Medical (09997) [3]

Summary of the Conference Call for Jingfeng Medical Industry Overview - The rise of high-end medical manufacturing in China is driving the development of domestic surgical robots, with companies like Jingfeng Medical showcasing differentiated advantages in remote and single-port surgical robots, particularly in developing countries where there is significant unmet clinical demand [2][3] Company Performance - Jingfeng Medical is recognized as a benchmark enterprise in the domestic laparoscopic surgical robot market, holding approximately 20% market share, second only to the Da Vinci system [4] - The company is expected to achieve significant overseas success, with installation and shipment volumes nearing 50 units by 2025, and rapid growth anticipated in 2026 [5] Financial Projections - Revenue forecasts for Jingfeng Medical are projected at 432 million yuan, 811 million yuan, and 1.232 billion yuan for the years 2025, 2026, and 2027 respectively [6] - A target price of 773.2 yuan or 79.57 HKD is set based on a 35x price-to-sales ratio for 2026, with an initial rating of "buy" [6] Core Technologies and Products - Jingfeng Medical is the first in China and the second globally to receive certifications for multi-port, single-port, and natural orifice surgical robots [7] - The flagship product, MSP2000, is the world's first integrated single-multi-port robotic surgical system, which received the C1 certification in October 2025 [7] Commercialization Progress - Since the commercialization of the multi-port laparoscopic surgical robot at the end of 2022, Jingfeng Medical has ranked first in domestic sales, covering over 220 hospitals across more than 30 provinces [8] - The company has signed sales agreements for 118 core products by the end of 2025, with 72 units destined for international markets, indicating a scaling global presence [8] Innovative Solutions - The company has launched a tri-modal surgical solution that integrates multi-port, single-port, and remote capabilities, reducing hospital acquisition costs and enhancing operational efficiency [9] - Its adaptability covers various laparoscopic surgical scenarios, including urology and gynecology, facilitated by high-precision control systems and low-latency remote systems [9] Management and R&D Strength - Founded by experienced professionals, Jingfeng Medical has a cross-disciplinary R&D team of 265 members, holding 453 authorized patents and 213 pending applications, ranking first among domestic peers [10] - The management team has extensive backgrounds in leading medical and precision instrument companies, providing a solid foundation for rapid growth [10] Future Development Prospects - With increasing installation volumes and enhanced product performance, the company is expected to achieve profitability by 2026, maintaining stable gross margins while expanding market penetration [11] - Continuous investment in R&D and marketing is anticipated to solidify its industry-leading position and drive further breakthroughs [11] Advantages of Robotic Surgery - Robotic surgical systems offer significant advantages over traditional laparoscopic surgery, including reduced impact from human factors like fatigue and emotion, and a wide range of applications across various medical fields [12] Market Comparison - The global laparoscopic surgical robot market is rapidly expanding, with projections indicating substantial growth in both installation volumes and market size through 2033 [16] - In China, the market is expected to grow significantly, with installation numbers projected to rise from 134 units in 2019 to 511 units by 2024, reflecting a compound annual growth rate of approximately 30% [20] Competitive Landscape - In China, 13 multi-port laparoscopic surgical robots have received regulatory approval, with 11 being domestic brands, showcasing a competitive local market [21] - Jingfeng Medical's products are noted for their affordability and advanced technology, allowing for widespread application in various hospital settings [21] International Expansion - Jingfeng Medical has established a robust commercialization team and has made significant strides in international markets, including obtaining CE certification in Europe and expanding into Southeast Asia [22][23] Conclusion - Jingfeng Medical is positioned for substantial growth in the surgical robot market, with innovative products, strong financial projections, and a commitment to expanding both domestic and international presence [24]

每经AI快讯，2月10日，精锋医疗-B(02675.HK)午后一度涨超12%，截至发稿涨11.33%，报64.85港元， 成交额3517.46万港元。 ...

国泰海通证券发布研报称，自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出 了20台精锋多孔腔镜手术机器人，在国内手术机器人制造商中排名第一。此外，2025年以来，精锋医疗 国际化引擎全速启动，海外订单量迎来爆发式增长，截至2025年底，公司已签订的118台核心产品的全 球销售协议中，海外国家占72台。 精锋医疗-B(02675)午后涨超12%，截至发稿，涨11.33%，报64.85港元，成交额3517.46万港元。 消息面上，国家医保局近日出台手术机器人收费指南。国信证券表示，受益于手术机器人行业技术革 新、临床需求及政策红利，全球及中国市场规模持续高速增长，其中中国单孔及自然腔道机器人细分赛 道增速尤为突出。建议积极关注国产手术机器人厂家的进口替代及出海进程。 ...